Table 3.
Susceptibility test results of 45 non-Enterobacterales (CRE) multidrug-resistant gram-negative bacteria (MDR-GNB) isolates from 41 patients.
| Non-Susceptible Isolates, n (%) | |||
|---|---|---|---|
| Antibiotic | Overall (n = 45) | P. Aeruginosa (n = 38) | ESBL-producing Enterobacterales (n = 7) |
| Amikacin | 25 (55.6) | 20 (52.6) | 5 (71.4) |
| Cefepime | 43 (95.6) | 36 (94.7) | 7 (100) |
| Ceftazidime | 40 (88.9) | 33 (86.8) | 7 (100) |
| Ceftolozane-tazobactam | 5 (11.1) | 4 (10.5) | 1 (14.8) |
| Ciprofloxacin | 41 (91.1) | 34 (89.4) | 7 (100) |
| Colistin | 12 (26.6) | 12 (31.5) | 0 |
| Gentamycin | 34 (75.6) | 29 (76.3) | 5 (71.4) |
| Imipenem | 35 (77.8) | 35 (92.1) | 0 |
| Meropenem | 33 (73.3) | 33 (86.8) | 0 |
| Piperacillin-tazobactam | 39 (86.7) | 34 (89.4) | 5 (71.4) |